We initiate coverage on Ion Exchange (India) Ltd as a BUY with a price objective of Rs 539, which represents a potential upside of 93% from the CMP of Rs 279
Ion Exchange, despite having a tepid performance over the last few years, is up for exciting times. Execution of the Sri Lanka project is expected to take its revenue growth trajectory higher along with a hefty improvement in margins from the Engineering segment. The US FDA nod for pharma resins is a shot in the arm as it is expected to be the next lever of growth in the chemicals segment. As a result, we expect overall revenues to grow at a CAGR of 16% over FY16-19, from Rs 869.5 crores in FY16 to Rs 1,371 crores in FY19....